Matthew Ellis
Medical Oncology · Houston, TXNPI 1669495685
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $267,243 of the $289,220 with a category attached, or 92.4%. Nanostring Technologies, Inc. accounts for 92.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $267,754 and has fallen 100.0% since, to $18 in 2023. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $5902.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nanostring Technologies, Inc.$267K
- Eli Lilly$7K
- Novartis$6K
- Astrazeneca UK Limited$4K
- Veracyte, Inc.$3K
- Covis Pharma GmbH$750
- plus $560 from 5 others
Across 1 payment — averaging $875.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$875
What the payments were for
- Royalty or licence$267,24392%
- Consulting fees$18,6736%
- Speaking & faculty fees$2,7001%
- Food & beverage$4370%
- Education$1680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nanostring Technologies, Inc. | 6 | $267,243 |
| Eli Lilly | 6 | $7,483 |
| Novartis | 2 | $6,375 |
| Astrazeneca UK Limited | 3 | $4,110 |
| Veracyte, Inc. | 7 | $2,700 |
| Covis Pharma GmbH | 1 | $750 |
| AstraZeneca | 5 | $306 |
| Pfizer | 16 | $167 |
| AbbVie | 1 | $58 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROSIGNA ASSAY$267,243
- PIQRAY$3,375
- KISQALI$3,000
How this compares
$289,220 in reported general payments places this provider in the 90th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.